Systemic Mastocytosis: Advances in Diagnosis and Current Management-Reference-Cited by-同舟云学术

Systemic Mastocytosis: Advances in Diagnosis and Current Management

Published:2021 Issue: Volume: Page:167-178
ISSN:0927-3042
Container-title:Cancer Treatment and Research
language:
Short-container-title:

Author:

Pullarkat Sheeja T.,Wu Winnie,Pullarkat Vinod

Publisher

Springer International Publishing

Link

https://link.springer.com/content/pdf/10.1007/978-3-030-78311-2_10

Reference26 articles.

1. Swerdlow SH et al (2017) WHO classification of tumours of haematopoietic and lymphoid tissues, revised 4th edn. International Agency for Research on Cancer, Lyon, France

2. Nagata H, Worobec AS, Oh CK et al (1995) Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci U S A 92:10560

3. Ustun C, Arock M, Kluin-Nelemans HC et al (2016) Advanced systemic mastocytosis: from molecular and genetic progress to clinical practice. Haematologica 101(10):1133–1143

4. Schaab J, Schnittger S. Sotlar K et al (2013) Comprehensive mutational profiling in advanced systemic Mastocytosis. Blood 12(14):460–466

5. Jawhar M, Schwaab J, Schnittger S et al (2016) Additional mutations in SRSF2, ASXL1 and or RUNX1identify a high risk group of patients with KIT D816V(+) advances systemic mastocytosis. Leukemia 30(1):136–143

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Diagnosis and management of systemic mastocytosis in a community hematology setting;Journal of Oncology Pharmacy Practice;2023-12-27

2. Mastocytosis in a Case of Noonan Syndrome Caused by a De Novo Pathogenic <i>CBL</i> Variant;Yonago Acta Medica;2023